D
espite the reported success of antidepressant drugs in the treatment of suicidal states, some studies suggest that antidepressant medications may have a paradoxical effect on a minority of patients, actually inducing suicidal states in susceptible individuals. [1] [2] [3] [4] Based on the available evidence in 2007, the US Food and Drug Administration (FDA) introduced a product labeling change concerning the use of all antidepressants in adults. This advisory suggested that during the "initial few months" of a course of antidepressant medication therapy or at times of dosage titration, "patients should be monitored for worsening suicidality and unusual changes in behavior, including anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania and mania. " 5 Although several methods to assess suicidality have been recommended (mostly in pediatric populations), 1, 6, 7 the need for a brief rating tool has yet to be met for clinical practice or research purposes.
Currently, available instruments to measure suicidal risk require interviews that typically evaluate both state-and trait-like ideation. A useful tool in practice should be able to monitor suicide-related factors to identify suicidal ideation and related symptoms and to be used as a repeated measure to detect changes in these factors over time. We developed the Concise Health Risk Tracking Self-Report (CHRT-SR) and Clinician Rating (CHRT-C) scales. These measures include questions about hopelessness, self-worth, pessimism about future, perception of social support, and active suicidal plans. Following the model set forth by Beck et al, 8 items were developed to encompass stages of escalating suicidality, from hopelessness about the future and lack of perceived support to nihilistic thinking or passive thoughts of death to active plans about death and suicide. Items were included in the questionnaire only if there was good face validity for the construct being assessed. To maximize clinical and research utility, the Concise Health Risk Tracking (CHRT) scale was designed to be used as either a patient self-report (CHRT-SR) or a clinician rating (CHRT-C).
This report presents psychometric data on the newly developed clinician-and self-rated versions of the CHRT scale in a group of 240 outpatients with nonpsychotic major depressive disorder (MDD) from primary and psychiatric care practice sites who were recruited as part of the Suicide Assessment Methodology Study conducted through the National Institute of Mental Health (NIMH)-funded Depression Trials Network.
METHOD

Study Description
The primary objective of the Suicide Assessment Methodology Study was to evaluate a brief clinicianand patient-rated measure of suicidal ideation and associated symptoms. Secondary objectives were to (1) describe and measure the occurrence and course of treatment-emergent suicidal ideation and associated symptoms in depressed outpatients after initiation and dose escalation of selective serotonin reuptake inhibitor (SSRI) pharmacotherapy and (2) evaluate suicidal ideation assessment methods in representative clinical psychiatric and primary practice settings.
This study was overseen by the Depression Trials Network National Coordinating Center (The University of Texas Southwestern Medical Center) and the Data Coordinating Center (Epidemiologic Data Center at the University of Pittsburgh) and conducted at 15 clinical sites. The institutional review boards at the National Coordinating Center, the Data Coordinating Center, and each participating site approved and oversaw the study protocol. A data safety and monitoring board reviewed the study protocol and participant consent prior to study enrollment and monitored participant safety throughout the study's course. The study is registered at clinicaltrials.gov (identifier NCT00532103).
Adult outpatients with nonpsychotic MDD, 18-75 years of age, were enrolled from July 2007 through February 2008 at 6 primary and 9 psychiatric care sites across the United States from the NIMH-funded Depression Trials Network. Major depressive disorder was diagnosed clinically and confirmed with the Psychiatric Diagnostic Screening Questionnaire (PDSQ) 9, 10 and an MDD checklist based upon the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR).
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Study participants were treated, open label, with an SSRI antidepressant medication and monitored for 8 weeks. The SSRIs used in the study included citalopram, escitalopram, fluoxetine, paroxetine, paroxetine controlled release, or sertraline, with the choice of the SSRI made by each individual participant's physician and recommended by clinical treatment guidelines. Clinical research coordinators at each clinical site supported participants in collecting all relevant rating instruments and assisted clinicians in the implementation of the protocol.
To provide appropriately vigorous yet tolerable dosing, clinical management was informed by critical decisionpoint dosing tables and utilized a measurement-based care treatment paradigm. [12] [13] [14] At each clinic visit depressive symptom severity was measured by using the 16-item Quick Inventory of Depressive SymptomatologyClinician Rating (QIDS-C 16 ), [15] [16] [17] a measure that captures the 9 DSM-IV-TR diagnostic criteria for a major depressive episode; scores range from 0 to 27, with higher numbers indicating greater severity. Side effects were assessed by the Systematic Assessment for Treatment Emergent Events-Systematic Inquiry, 18 a 55-item self-report that rates the most commonly reported side effects associated with pharmacologic interventions, and by the 3-item Frequency, Intensity, and Burden of Side Effects Rating, 19 a self-report measure that provides global ratings of frequency, intensity, and overall burden due to side effects attributable to the antidepressant medication. Adherence to the prescribed antidepressant was assessed with a self-rated medication adherence questionnaire. Protocol treatment visits were to occur at weeks 0, 2, 4, 6, and 8. In addition, the QIDS-C 16 and the Frequency, Intensity, and Burden of Side Effects Rating were collected by phone at weeks 1, 3, 5, and 7. During the first 2 weeks following medication initiation and following a dose increase (week 4 or later), participants were contacted by telephone on Mondays, Wednesdays, and Fridays to evaluate the presence of suicidal ideation and for the emergence of associated symptoms as assessed by the CHRT-C.
Study Population
Eligible outpatients seeking care for depression provided written informed consent and were enrolled at 15 psychiatric and primary care clinical sites in the Depression Trials Network. Eligible participants scored ≥ 14 on the baseline 17-item Hamilton Depression Rating Scale (HDRS 17 ). 20, 21 Participants with general medical conditions were eligible as long as their general medical conditions did not contraindicate the use of SSRI treatment. Patients were ineligible if they had bipolar disorder; schizophrenia; schizoaffective disorder; MDD with psychotic features (lifetime); a current primary diagnosis of anorexia nervosa, bulimia nervosa, or obsessive-compulsive disorder; current diagnosis of substance abuse or dependence; required inpatient treatment at the time of study entry; or had a well-documented history of nonresponse (in the current major depressive episode) to 2 adequately delivered SSRI treatments (in terms of both dose and duration). Patients were also ineligible if they were breast-feeding, pregnant, or intending to become pregnant; had taken an antipsychotic medication within 4 months of study entry; or had taken antidepressants in the 2 weeks prior to screening (4 weeks for fluoxetine and 6 weeks for monoamine oxidase inhibitors). The presence of suicidal ideation was allowed as long as acute inpatient treatment was not indicated at the baseline visit.
Assessments
At the screening/baseline visit, clinical research coordinators collected clinical and sociodemographic information and completed the HDRS 17 by direct interview. At baseline,
Clinical Points
Use of standardized measures to monitor suicide risk is ■ essential in the care of patients with depression.
The Concise Health Risk Tracking (CHRT) scale is a brief, ■ easy-to-use rating instrument for suicide risk.
The CHRT scale can be used in routine clinical care with ■ minimal burden.
participants also completed a 125-item forced-choice (symptom present or absent) self-report DSM-IV Axis I screening questionnaire; the PDSQ 9, 10 ; and the Self-Administered Comorbidity Questionnaire, 22 a 40-item self-report that assesses the presence of a range of common medical conditions, their severity, and whether or not the conditions limit functioning.
During all clinic visits, including baseline, the clinical research coordinators also collected the QIDS-C 16 , the Frequency, Intensity, and Burden of Side Effects Rating; the Systematic Assessment For Treatment Emergent EventsSystematic Inquiry; the patient adherence measure; the Positive and Negative Suicide Ideation Inventory 23 (a 20-item self-report of positive and negative thoughts related to suicide attempts); the Modified Scale of Suicidal Ideation 6 (an 18-item clinician-administered scale that monitors intensity of ideation, courage and competence to attempt, and talk and writing about death over the past year); and the 21-item Beck Anxiety Inventory 24, 25 self-report of physiologic hyperarousal and cognitive anxiety over the last week. At baseline and at each clinic visit, patients and the clinical research coordinators also collected the CHRT-SR and CHRT-C.
At each of the Monday, Wednesday, and Friday phone calls for 2 weeks after dose initiation and again at dose increase, the clinical research coordinators completed the CHRT-C.
These calls took place the first 2 weeks after the initiation of SSRI treatment, and again for 2 weeks if the dosage was changed, either increased or decreased.
CHRT-C and CHRT-SR were originally developed to include 12 items reflecting the following domains: (1) hopelessness, (2) interpersonal attachment/social support, and (3) active suicidal ideation and behavior. Each of the items is presented as a statement and the extent to which it is applicable to the preceding 24 hours is rated on a 5-point, fully anchored, Likert scale, with responses ranging from "strongly agree" to "strongly disagree" for all items (CHRT-SR; Figure 1 ).
Analytic Methods
Descriptive statistics, percentages for discrete characteristics, and measures of central tendency for continuous characteristics were used to describe the sample. Of the baseline sample (n = 265), 25 patients were not included in the analysis due to incomplete data. All analyses were conducted on baseline data separately for the CHRT-C and the CHRT-SR. Spearman rank correlation coefficients are used to assess inter-item correlations. The factor structure was evaluated using a principal component analysis. The Goodness-of-Fit Index (GFI) was used to assess the fit of the factor structure. The GFI ranges between 0 and 1, with higher scores 
indicating a better fit. Pearson correlation coefficients were used to assess the association of the total score of the CHRT scale with each of the factors and to estimate the discriminant and concurrent validity by evaluating the correlations of the CHRT scale total score with other measures of mood disorders, suicidal ideation, and general medical comorbidity burden.
RESULTS
Two hundred eighty-nine subjects were screened, of which 24 were ineligible and 25 had missing data items in either the CHRT-C or the CHRT-SR. Hence, the evaluable sample included 240 male (n = 70) and female (n = 170) outpatients with nonpsychotic MDD, from 18 to 65 years of age Table 2 provides results of the principal component analyses. An examination of the scree plot of eigenvalues indicated 3 orthogonal factors should be retained. Within the 3-factor solution for both 12-item versions of the CHRT, items 5, 7, and 8 (passive suicidal ideation) cross-loaded on 2 factors and were excluded from subsequent analysis. Factor analysis on the remaining 9 items found 2 items (1 and 3, pessimism about the future) cross-loading on 2 factors of the CHRT-SR and these items were, therefore, dropped. Analysis of the resultant 7-item versions of the CHRT-C (CHRT-C 7 ) (GFI = 0.985) and CHRT-SR (CHRT-SR 7 ) (GFI = 0.979) provided an excellent goodness of fit for the 3-factor solution, with no cross-loading items, and a consistent factor structure across both versions of the CHRT 7 . The 3 factors identified include hopelessness, perceived lack of social support, and active suicidal thoughts and plans. Table 3 provides inter-item correlations for both the CHRT-C 7 and CHRT-SR 7 . High item-item correlations were observed for active suicidal ideation (items 10 and 11) and plans (item 12). There were acceptable item-item correlations for questions associated with social support (items 2 and 9), and hopelessness (4 and 6). Comparable correlations were observed for both the self-and clinician-rated versions. Table 4 provides the distribution of items endorsed at baseline in the 2 versions of the CHRT 7 . The more severe items, active suicidal thoughts and plans, were endorsed by fewer patients than were the nihilistic thinking, social support, and hopelessness items, as might be expected.
Exploratory Factor Analyses
Item-Item Correlation
Distribution of Responses to Items
Reliability
Cronbach α for the 7-item versions were .77 (CHRT-C 7 ) and .78 (CHRT-SR 7 ). There was also a high agreement between the self-rated and clinician-rated items of the CHRT scale (Table 5 ) with κ ranging from 0.63 to 0.81.
Summary Statistics and Factor
Scores of the CHRT-C 7 and CHRT-SR 7 Table 6 provides total scores on the CHRT-C 7 and CHRT-SR 7 as well as the 3 factors. Each factor revealed a correlation with the total scale score of 0.70 to 0.75 across the CHRT-C 7 and CHRT-SR 7 . The 3 factors each show a low correlation with each other. Table 7 provides correlations of CHRT-C 7 and CHRT-SR 7 with other standard suicide scales and measures of depression, anxiety, and general medical comorbidity. As expected, the strongest association was with the positive symptom scale from the Positive and Negative Suicide Ideation Inventory, and with the HDRS 17 , while there were fewer associations with general medical comorbidity burden.
Correlation of CHRT-C 7 and CHRT-SR 7 With Measures of Suicidal Ideation and Depressive Symptom Severity
DISCUSSION
The clinician and self-report versions of the CHRT 7 are best defined by a 3-factor structure consisting of indices of active suicidal ideation and plans (items 10, 11, and 12), perceived lack of social support (items 2 and 9), and hopelessness (items 4 and 6).
The 3 CHRT 7 items representing the active suicidal thoughts and plans factor (items 10, 11, and 12) may show the most clinical utility as indicators of imminent risk. However, the additional items including the hopelessness and the perceived lack of social support items most likely have additional value for predicting future suicidal ideation. 26 All 3 factors have been consistently shown to be associated with suicidal behavior. 8, 26 Interest ing ly, suicid a l thoughts and plans were more likely to be endorsed by patients than by clinicians, and clinicians were less likely to use the more extreme rating ("strongly agree"). These results suggest the possibility that some patients may be more willing to endorse suicidal ideation on self-report assessments or that some physicians may be reluctant to record suicidal ideation. Findings from Mundt et al 27 support the feasibility of assessing suicidality using an Interactive Voice Response computer version of the Columbia Suicide-Severity Rating Scale. While the need for directly querying patients about suicidal ideation, plans, and intent in order to provide an appropriate treatment and safety response is evident, the frequency of positive responses to these questions is relatively low for outpatients with MDD, suggesting the importance of including potential precursors or associated indicators of suicidality, such as lack of social support and a sense of hopelessness or powerlessness. These factors, which are also associated with suicidal ideation, provide additional opportunities to detect a need for clinical evaluation and possible intervention.
The current accepted standard for quantifying and qualifying existing suicidality is the Columbia Classification Algorithm of Suicide Assessment (C-CASA), 7 which categorizes suicidality into acts preparatory to a suicidal (F1, F2, F3 ). For example, for the 12-item CHRT-C, factor 1 is defined by items 5, 7, 8, 10, 11, and 12; for the 7-item CHRT-C, factor 1 is defined by items 10, 11, and 12. Abbreviations: F1 = factor 1, F2 = factor 2, F3 = factor 3.
act, self-harm behaviors with and without suicidal intent, suicidal acts with and without suicidal intent, and actual completed suicide. The C-CASA system provides clinically essential details allowing for the accurate evaluation of suicidal intent and action. In response to the C-CASA criteria, a brief clinician-rated CHRT scale behavioral module has been developed that, when combined with the CHRT-SR or CHRT-C, maps to the C-CASA rating system, consistent with FDA reporting requirements. The assessment of behavioral symptoms, such as preparatory acts, and self-harm behaviors in addition to clinical symptoms (suicidal ideation, hopelessness, social isolation) provide clinicians with additional information necessary to evaluate patient safety. Currently, the Columbia Suicide-Severity Rating Scale 28, 29 is the assessment of choice to document C-CASA criteria in clinical trials. The CHRT scale system offers a brief alternative to traditional ratings of suicidality. The CHRT (SR or C version) may be used alone as a screening device to identify patients with suicidal ideation or for those desiring to map C-CASA, in combination with the CHRT scale behavior module.
The clinician and self-report versions of the CHRT 7 have comparable psychometric properties. The internal consistency for both versions is good, and the factor structures are almost identical. Both versions provide comparable GFIs. The 7-item CHRT (C or SR version) provides a quick (1 to 2 minutes), easy to administer evaluation of suicidal ideation and related factors. Given the recent recognition of the possibility that increased suicidal ideation is associated with a wide variety of medications, the development of a quick and effective means to identify, quantify, and qualify treatment-emergent suicidal ideation for use in both clinical and research settings appears timely.
The current study is limited by several factors: (1) the study sample size is modest, though the sample was drawn from a range of clinical settings; (2) the psychometric properties of the CHRT 7 have not been replicated; (3) the CHRT 7 is suitable to document suicidal ideation but requires the behavioral module, which was subsequently developed to provide complete coverage of the C-CASA; (4) while we were able to present data supporting the measures' content and construct validity, criterion and predictive validity requires a large epidemiologic sample to determine if scale scores predict suicidal attempts; (5) the sample size precluded the stratification for analysis by subgroups of specific interest, such as young adults; (6) the sensitivity of the scales to change over time (worsening or improvement) remains to be examined; and (7) the scales have not been used with children, adolescents, or the elderly. On the other hand, the naturalistic design allowed for the collection of data from a highly representative sample of outpatients with nonpsychotic MDD.
In summary, both CHRT 7 assessments possess acceptable psychometric properties and are easy to use in practice. The self-rated instrument performed as well as the clinician-rated version. The 3 factors (suicidal ideation/plans, hopelessness, perceived lack of social support) have excellent face validity and they identify different domains that have been related to suicidal behavior in other studies in the past. To determine whether CHRT scale ratings predict suicide attempts or completions would require a much larger prospective study.
